Silo Pharma Inc SILO 深 沪
已收盘 03-27 16:00:00 美东时间
0.34
-0.039
-10.29%
华盛通- 最 高0.3769
- 今 开0.3702
- 成交量 14.46万股
- 最 低 0.34
- 昨 收 0.379
- 总市值 481.66万
- 52周最高 1.19
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 0.221
- 委 比 11.98%
- 总股本 1416.66万
- 历史最高 7.26
- 量 比 0.46
- 振 幅 9.74%
- 历史最低 0.221
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock rose 17.6% to $5.88 during Wednes...
03-04 20:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Vir Biotechnology (NASDAQ:VIR) shares moved upwards by 65.0% to $12.26...
02-24 20:05
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies Inc (NYSE:KEYS) rose sharply in pre-market trad...
02-24 18:21
Silo Pharma Board Authorizes $1 Million Share Repurchase Program
Silo Pharma Board Authorizes $1 Million Share Repurchase Program Silo Pharma Inc.’s board of directors authorized a share repurchase program for up to $1 million of the Company’s common stock. The program permits repurchases in the open market, through privately negotiated transactions, or otherwise
02-24 06:01
BRIEF-Silo Pharma Announces Share Buyback Program
BRIEF-Silo Pharma Announces Share Buyback Program Feb 23 (Reuters) - Silo Pharma Inc SILO.O : SILO PHARMA ANNOUNCES SHARE BUYBACK PROGRAM SILO PHARMA INC - ANNOUNCES $1 MILLION SHARE REPURCHASE PROGRAM Source text: ID:nGNX4WjH1v Further company coverage: SILO.O (( Reuters.Briefs@thomsonreuters.com ;
02-24 05:55
Silo Pharma Announces $1M Buyback Plan
Silo Pharma, Inc. (NASDAQ:SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has
02-24 05:20
Silo Pharma Gets Notice Of Allowance From Japan Patent Office For Patent Application Covering SPC-15
Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic
02-18 21:29
Silo Pharma Receives Japan Notice of Allowance for SPC-15 PTSD Intranasal Therapy Patent Application
Silo Pharma Receives Japan Notice of Allowance for SPC-15 PTSD Intranasal Therapy Patent Application Silo Pharma Inc. said the Japan Patent Office issued a Notice of Allowance for a patent application covering its lead asset SPC-15, an intranasal therapeutic targeting PTSD. The application includes
02-18 21:28
Silo Pharma Signs Non-Binding Letter Of Intent With Allucent To Offer Clinical Research Services For Two Phase 1 Trials Of SPC-15 Nasal Spray
Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for
2025-12-30 21:07
BRIEF-Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd
Silo Pharma Inc SILO.O: SILO PHARMA PARTNERS WITH ALLUCENT TO SUPPORT PLANNED FDA INVESTIGATIONAL NEW DRUG APPLICATION FOR SPC-15 AS A THERAPEUTIC FOR PTSD SILO PHARMA INC - EXPECTS IND SUBMISSION IN ...
2025-11-17 21:17
